You are using an out of date browser. It may not display this or other websites correctly. You should upgrade or use an alternative browser.
Based on its advanced neoantigen prediction platform and in vitro evaluation platform, Creative Biolabs has continued to build a TCR-T therapy that can target tumor-specific neoantigen, which will become a major weapon for cancer treatment.
